Last updated: about 1 month ago
AstraZeneca's Imfinzi: EMA's Positive Nod for NSCLC Treatment Breakthrough
AstraZeneca's Imfinzi receives EMA approval recommendation for NSCLC. AEGEAN trial shows significant recurrence reduction, enhancing patient outcomes and market potential.